PIERREL RESEARCH ANNOUNCES €2.4 MM AWARD FROM TOP 5 PHARMA SPONSOR

PIERREL RESEARCH ANNOUNCES €2.4 MM AWARD FROM TOP 5 PHARMA SPONSOR

Zurich, Switzerland, 31 July 2013 – Pierrel Research, a global full-service CRO, today announced that it has been selected by a Top 5 pharmaceutical sponsor to conduct its Phase IV Ophthalmology trial in 11 countries over 2 years.

Pierrel Research Group has more than 20 years experience as a full-service Contract Research Organization (CRO) providing drug development services to the pharmaceutical, biotechnology, and medical device industries as well as full IMP services. With clinical staff strategically located in over 20 offices worldwide, enabling a high level of local expertise to be applied to global clinical trials of all sizes. Our international and highly skilled multidisciplinary teams work to consistently offer high quality, flexible and cost effective services and solutions across the full spectrum of clinical research and regulatory requirements.

Pierrel also offers consultancy services for clinical and regulatory development programs as well as operational services to effectively conduct global Phase I - IV programs, Late Phase, and Non-Interventional Studies (NIS). Global Headquarters are in Zurich, Switzerland, with Operational Headquarters in Essen, Germany, Philadelphia, United States, and Saint-Petersburg, Russia.

Media Contact:
Maxime Stevens
Tel: +39 02 24134 206
[email protected]

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.